4 February, 2020
Financial markets are reeling as a result of the coronavirus outbreak. While the experience with Severe Acute Respiratory Syndrome (SARS) from some years back suggests calm would be restored soon, good sense and logic can remain in short supply in the meantime. Frances Donald and Sue Trinh from our macroeconomic strategy team take a closer look.
As we head into February, we see three key macroeconomic themes that are likely to interrupt the global economic recovery narrative and the associated reflation trade: the coronavirus and its impact on economic growth, how global growth has yet to hit a trough which would then set the stage for a recovery, and finally, how markets might have underpriced the likelihood of further monetary easing from global central banks.
The outbreak of 2019-nCov, more widely known as the coronavirus, is first and foremost a human tragedy, but the market is left with the unenviable task of forecasting and pricing an event that is evolving by the hour.
From an economic perspective, we believe the coronavirus represents, at best, a one-to-two quarter data distortion and, at worst, a hit to the global services sector—the pillar of global growth. Either way, it’s enough to convince investors to adopt a more defensive position. This isn’t surprising, since it substantially reduces our visibility on the global macro landscape and, particularly, the magnitude and timing of China’s much-hoped-for recovery.
While we view the coronavirus as an exogenous, sizable demand shock that also carries supply chain implications, the extent of the economic damage it can inflict will depend on the degree to which it alters consumer behavior and corporate response to the outbreak globally.
At this juncture, any claims to forecasting accuracy should be taken with a healthy pinch of salt. Past experiences (SARS in the fourth quarter of 20021 , the avian flu in late 2003/early 2004, and the swine flu in the first half of 2009) could provide some insight.
Here’s what we’ve seen so far2 :
Based on historical analysis on SARS, it’s likely that Chinese GDP will slip below 6% in the first quarter and second quarter. The official response has been swift, and the measures introduced have been more aggressive, particularly with respect to travel bans. The implication here is that we’re likely to see a quicker, deeper hit to economic growth and a delay in the consensus “China is stabilising” theme.
That said, it’s possible that the various economic models that have been used to generate these estimates could have underestimated the potential impact of the current outbreak.
While economic growth, as well as the financial markets, rebounded quickly after the SARS outbreak 17 years ago, it’s worth noting that China was in the early stages of a decade-long economic boom then following its ascension to the World Trade Organisation. The macroeconomic context today is very different.
Additionally, annual domestic travel in China has risen 4.5-fold since 2003, and international travel has become even more popular (up 7.6 times compared with 2003). 3 As such, the risk of virus transmission and the negative impact on international tourism is much higher today.
Let’s also not forget that Wuhan plays a strategic role in the Chinese economy—it’s a hub for transport, trade, and industry in Central China. The city’s GDP growth in 2019 was 7.8% (on a year-onyear basis), outpacing the national rate of 6.0%. It’s now forecast to grow just 6.0% this year.2
Meanwhile, the macroeconomic backdrop hasn’t changed; China’s ability to revive growth is much more constrained relative to 2003. All things considered, we believe investors can expect:
Outside of China, we’re also expecting developed markets to experience a more subdued, but no less relevant, confidence shock. As the virus spreads and the number of confirmed cases rises, the services sector could come under pressure. We’re monitoring global housing and retail sales activity closely. These data points may be somewhat distorted in January/February but we don’t expect this to be a game changer, yet.
A significant decline in Chinese tourists could also have important implications for the region’s economies, particularly those that are more reliant on the Chinese tourist expenditure, such as Thailand, Cambodia, Hong Kong, and Vietnam.
In our 2020 outlook, we posited that a mild global rebound will take place in the second half of the year. In our opinion, the recovery will be supported by low rates and cyclical sectors (housing), a bottoming in sentiment data, a stabilisation in China, and a gradual inventory restocking. Our view hasn’t changed, although there’s undoubtedly greater uncertainty in regard to the performance of China’s economy.
However, at present, the first quarter remains to be a “pain point” for US (and global) growth as the global manufacturing/trade recession and supply chain shocks work their way through the system. Taking a longer -term perspective, we believe this will ultimately represent a buying opportunity, but in the meantime, it’s likely to produce short -term macro -generated risk -off sentiment, amplified by the coronavirus outbreak.
The risk for central banks is asymmetric: We believe there’s a lot more scope for interest -rate cuts to be priced into the market in the coming weeks, even if the trigger isn’t eventually pulled. Both the Bank of England and the Bank of Canada, both of which had until recently retained a hawkish view of monetary policy, made dovish noises in January —the development could well set the tone for what is to come. In truth, within the current environment, we believe the Fed will have no choice but to move even further into “dovish territory,” or risk tightening financial conditions further.
Up until the emergence of the coronavirus outbreak, the first few weeks of 2020 have been relatively calm. Monetary policy remains easy, and the global economy has been displaying early signs of recovery, which we believe will take hold in the second half of the year. From a macroeconomic perspective, we don’t expect the coronavirus outbreak to materially alter that narrative. In terms of positioning, while it makes sense to adopt a relatively more defensive approach in the short term, we believe the current “interruption” could be seen as an opportunity from a more strategic perspective and we continue to expect equities to end the year higher.
1 SARS ended by July 2003: https://www.who.int/ith/diseases/sars/en/
2 Bloomberg, Macrobond, as of 31 January 2020
3 National Bureau of Statistics of China, Macrobond, Manulife Investment Management, as of 31 January 2020
The case for China bonds: A potential hedge against rising inflation
We explain why they think China government bonds and the Chinese renminbi have the potential to act as hedges against US inflation.
ESG investing in Asia - the continuing evolution
As ESG investing in Asia surges, we discuss the key developments in the region’s sustainable fixed-income market and how to identify meaningful investment opportunities for a sustainable future.
Banks are back: a look at three stages of U.S. bank recovery
We explore how U.S. banks prepared to weather the economic tail risk of a pandemic and discuss why we maintain a favorable view of the segment amid prospective signs of continued strength for banks.